ClinicalTrials.gg
CompletedNCT01594515Updated Dec 15, 2015Results posted

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

A Phase 1 interventional study of BI 1015550 and BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-15.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

In this first-in-man trial, safety, tolerability, pharmacokinetics, and selected pharmacodynamics parameters of BI 1015550 will be assessed in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
70 participants (actual)

Study arms

  • Experimental
    BI 1015550 low dose A

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 low dose B

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 low dose C

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 low dose D

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 medium dose A

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 medium dose B

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 medium dose C

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 high dose A

    Powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 high dose B

    Powder for oral solution

    Drug: BI 101550

  • Placebo comparator
    Placebo

    Solution for oral administration

    Drug: Placebo

Interventions

  • High dose powder for oral solution

  • Medium dose powder for oral solution

  • Low dose powder for oral solution

  • Low dose powder for oral solution

  • Low dose powder for oral solution

  • DrugPlacebo

    Solution for oral administration

  • DrugBI 101550

    High dose powder for oral solution

  • Low dose powder for oral solution

  • Medium dose powder for oral solution

  • Medium dose powder for oral solution

06

What researchers measure

Primary outcomes

  1. Number (%) of Subjects With Drug Related Adverse Events

    Percentage of subjects with drug related adverse events.

    Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.

  2. Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests

    Percentage of subjects with clinically relevant abnormalities in clinical laboratory tests (haematology, clinical chemistry, haemoccult® test, and urinalysis).

    Time frame: Day -21 to -2, upto -72 hours, 4h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).

  3. Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs

    Percentage of subjects with clinically relevant abnormalities in vital signs (blood pressure, pulse rate, respiratory rate, oral body temperature, orthostasis test).

    Time frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).

  4. Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs

    Percentage of subjects with clinically relevant abnormalities in 12-lead ECGs.

    Time frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).

  5. Number (%) of Subjects With Clinically Relevant Abnormalities in Tolerability

    Percentage of subjects with clinically relevant abnormalities in tolerability assessed by the investigator.

    Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.

  6. Number (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations

    Percentage of subjects with clinically relevant abnormalities in physical examinations.

    Time frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.

Secondary outcomes

  1. Cmax of BI 1015550

    Maximum measured concentration of the analyte in plasma.

    Time frame: -0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing

  2. AUC0-infinity of BI 1015550

    Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity

    Time frame: -0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing

07

Results

Posted Dec 15, 2015
Limitations and caveats
BI 1015550 high dose 24mg was originally planned as 26 mg but reduced due to PK interim analysis results of previous dose group.

Participant flow

70 patients were treated and analysed.

Participant flow — Overall Study
MilestoneBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Started66666666616
Completed66666666616
Not completed0000000000

Outcome measures

PrimaryNumber (%) of Subjects With Drug Related Adverse Events

Percentage of subjects with drug related adverse events.

Time frame:
From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Drug Related Adverse Events
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Drug Related Adverse Events0.033.316.70.00.033.316.716.716.76.3
PrimaryNumber (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests

Percentage of subjects with clinically relevant abnormalities in clinical laboratory tests (haematology, clinical chemistry, haemoccult® test, and urinalysis).

Time frame:
Day -21 to -2, upto -72 hours, 4h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests0.00.00.00.00.00.00.00.00.00.0
PrimaryNumber (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs

Percentage of subjects with clinically relevant abnormalities in vital signs (blood pressure, pulse rate, respiratory rate, oral body temperature, orthostasis test).

Time frame:
Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs0.00.00.00.00.00.00.00.00.00.0
PrimaryNumber (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs

Percentage of subjects with clinically relevant abnormalities in 12-lead ECGs.

Time frame:
Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGs0.00.00.00.00.00.00.00.00.00.0
PrimaryNumber (%) of Subjects With Clinically Relevant Abnormalities in Tolerability

Percentage of subjects with clinically relevant abnormalities in tolerability assessed by the investigator.

Time frame:
From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Clinically Relevant Abnormalities in Tolerability
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Clinically Relevant Abnormalities in Tolerability0.00.00.00.00.00.00.00.00.00.0
PrimaryNumber (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations

Percentage of subjects with clinically relevant abnormalities in physical examinations.

Time frame:
From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Reported as:
Number · Percentage of Participants
Number (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations
Percentage of ParticipantsBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlacebo
Number (%) of Subjects With Clinically Relevant Abnormalities in Physical Examinations0.00.00.00.00.00.00.00.00.00.0
SecondaryCmax of BI 1015550

Maximum measured concentration of the analyte in plasma.

Time frame:
-0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing
Reported as:
Geometric mean · nmol/L
Cmax of BI 1015550
nmol/LBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mg
Cmax of BI 1015550NA ± NA1.42 ± 23.25.02 ± 20.113.7 ± 14.246.9 ± 38.9113 ± 20.4176 ± 12.6292 ± 22.2542 ± 12.1
Statistical analysis
  • BI 1015550 Low Dose 0.06mg vs BI 1015550 Low Dose 0.2mg vs BI 1015550 Low Dose 0.6mg vs BI 1015550 Medium Dose 2mg vs BI 1015550 Medium Dose 4mg vs BI 1015550 Medium Dose 8mg vs BI 1015550 High Dose 16mg vs BI 1015550 High Dose 24mg · Slope: 0.9702 · 95% CI 0.9400 to 1.0005Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.
SecondaryAUC0-infinity of BI 1015550

Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity

Time frame:
-0.5hour before dosing and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after dosing
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity of BI 1015550
nmol*h/LBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mg
AUC0-infinity of BI 1015550NA ± NA7.44 ± 12.724.1 ± 13.967.9 ± 15.6287 ± 14.9679 ± 32.01210 ± 18.32180 ± 19.93650 ± 22.6
Statistical analysis
  • BI 1015550 Low Dose 0.06mg vs BI 1015550 Low Dose 0.2mg vs BI 1015550 Low Dose 0.6mg vs BI 1015550 Medium Dose 2mg vs BI 1015550 Medium Dose 4mg vs BI 1015550 Medium Dose 8mg vs BI 1015550 High Dose 16mg vs BI 1015550 High Dose 24mg · Slope: 1.0442 · 95% CI 1.0145 to 1.0740Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.

Adverse events

Collected over From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/16 (0%)5/16 (31.3%)
BI 1015550 Low Dose 0.02mg—0/6 (0%)2/6 (33.3%)
BI 1015550 Low Dose 0.06mg—0/6 (0%)2/6 (33.3%)
BI 1015550 Low Dose 0.2mg—0/6 (0%)3/6 (50%)
BI 1015550 Low Dose 0.6mg—0/6 (0%)3/6 (50%)
BI 1015550 Medium Dose 2mg—0/6 (0%)1/6 (16.7%)
BI 1015550 Medium Dose 4mg—0/6 (0%)3/6 (50%)
BI 1015550 Medium Dose 8mg—0/6 (0%)3/6 (50%)
BI 1015550 High Dose 16mg—0/6 (0%)2/6 (33.3%)
BI 1015550 High Dose 24mg—0/6 (0%)3/6 (50%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboBI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mg
HeadacheNervous system disorders1/160/61/61/61/61/62/62/60/60/6
Ear discomfortEar and labyrinth disorders0/161/60/60/60/60/60/60/60/60/6
Abdominal painGastrointestinal disorders0/160/60/60/60/60/61/60/61/60/6
DiarrhoeaGastrointestinal disorders1/160/60/61/60/60/61/60/60/60/6
Lip dryGastrointestinal disorders0/160/60/61/60/60/60/60/60/60/6
NauseaGastrointestinal disorders0/160/60/60/60/60/60/61/60/60/6
VomitingGastrointestinal disorders0/160/60/60/60/60/60/61/60/60/6
Application site irritationGeneral disorders0/160/60/60/61/60/60/61/61/60/6
FatigueGeneral disorders0/160/61/60/60/60/60/61/60/60/6
Oral herpesInfections and infestations0/160/60/60/60/60/60/60/60/61/6

Baseline characteristics

The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least 1 dose of the investigational treatment.

Age, Continuous
Age, Continuous(Years)BI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlaceboTotal
Mean33.5 ± 5.129.5 ± 4.838.2 ± 6.535.0 ± 5.535.5 ± 5.932.7 ± 5.936.3 ± 6.340.5 ± 3.333.5 ± 8.436.6 ± 5.635.3 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 Low Dose 0.02mgBI 1015550 Low Dose 0.06mgBI 1015550 Low Dose 0.2mgBI 1015550 Low Dose 0.6mgBI 1015550 Medium Dose 2mgBI 1015550 Medium Dose 4mgBI 1015550 Medium Dose 8mgBI 1015550 High Dose 16mgBI 1015550 High Dose 24mgPlaceboTotal
Female00000000000
Male6666666661670
08

Study locations

1 site
  • 1305.1.1 Boehringer Ingelheim Investigational Site
    Ingelheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2012
First posted
May 9, 2012
Start
May 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Dec 15, 2015
Last update
Dec 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01594515
Responsible party
Sponsor
First posted
May 9, 2012
Start date
May 2012
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Dec 15, 2015
Last update
Dec 15, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion